Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
33%
Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Active, not recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

active_not_recruiting133%
recruiting133%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_1

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

NCT07204977
recruitingphase_4

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
completedphase_3

Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence

NCT03634917

Clinical Trials (3)

Showing 3 of 3 trials
NCT07204977Phase 1

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

Active Not Recruiting
NCT06269627Phase 4

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

Recruiting
NCT03634917Phase 3

Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3